Background: The cyclin-dependent kinase inhibitors p15
Introduction
Vulvar carcinoma is a rare female genital malignancy with an incidence ranging from 1 to 2 per 100 000 person-years worldwide [1, 2] . Vulvar cancer has mainly been linked to elderly women but an increasing incidence among younger women has been reported recently [3, 4] . The standard treatment with radical surgery is associated with a considerable morbidity [1] . Thus, it is important to make individualized treatment procedures in order to reduce negative effects for patients with a good prognosis. The identification of new biomarkers could possibly improve the prediction of clinical outcome and may also be important for development of better treatment strategies.
Cyclin-dependent kinase inhibitors (CDKI), the major inhibitors of the cell cycle, are divided into the INK4 and CIP/KIP family. The INK4 members includes p15 INK4b , p16
INK4a , p18 INK4c and p19 INK4d/ARF (p14 ARF in humans), whereas the CIP/KIP members includes p21 CIP1 , p27 KIP2 and p57 KIP2 [5, 6] . INK4 protein binds specifically to the CDK4 and CDK6 complexes, causing G1 arrest. The CIP/KIP family has a broader specificity for CDKs also inhibiting the other cyclin-CDK complexes at a later stage of the cell cycle [5, 6] . Previously p14 ARF , p15 INK4b , p16 INK4a , p21 CIP1 and p27 KIP2 have been found to be involved in the neoplastic process of vulvar carcinomas [7] [8] [9] , however only a limited number of cases has been investigated for p15
INK4b [9] . Furthermore, to our knowledge, there has been no study of p57 KIP2 in vulvar carcinomas. The loss of p15
INK4b and p57 KIP2 function occurs frequently in a variety of human cancers suggesting that its down-regulation may be important in neoplastic transformation [10] [11] [12] [13] [14] [15] [16] [17] [18] . Furthermore, an association has been found between abnormality of p15
INK4b and p57 KIP2 and unfavorable outcome [14, 17, [19] [20] [21] [22] [23] . The aim of our study was to investigate the expression of p15
INK4b and p57 KIP2 in a large series of vulvar squamous cell carcinomas to clarify their potential prognostic values.
Methods

Patient materials
Between 1977 and 2006, 297 patients had been diagnosed with vulvar squamous cell carcinoma at The Norwegian Radium Hospital. The median age at diagnosis was 74 years (range 35-96 years). Surgical radicality in the vulvar specimen (no rest tumor) was obtained in 198 (67%) of the patients and the remaining 99 (33%) patients did not obtain surgical radicality. Prior to surgery, radiotherapy was given to six patients and three cases received radiotherapy/chemotherapy. Postoperative irradiation was administered to 63, chemotherapy to three and irradiation/ chemotherapy to four of the patients. After treatment, the patients have been followed at The Norwegian Radium Hospital or at a local hospital. The histological specimens were reevaluated by an experienced pathologist (J.M.N) according to World Health Organization recommendations [25] . Two hundred and eighty (94%) tumors were keratinizing/nonkeratinizing, 13 (5%) were basaloid and 4 (1%) were veruccoid. Thirty-six samples of normal vulva form patients, undergoing surgery for benign gynecological diseases, were included as controls. Results obtained from our previous studies on cell cycle proteins in this same cohort of vulvar carcinomas [7, 8, 26] were co-analyzed with those of the current study.
Immunohistochemistry
Sections from formalin-fixed, paraffin-embedded tissues were immunostained using the Dako EnVision TM Flex+ System (K8012; Dako, Glostrup, Denmark) and the Dako Autostainer. Deparaffinization and the unmasking of epitopes were performed using PT-Link (Dako) and EnVision TM Flex target retrieval solution at a high pH for p15
INK4b and low pH for p57 KIP2 . To block endogeneous peroxidase the sections were treated with 0.3% hydrogen peroxide (H 2 O 2 ) for 5 min. Sections were incubated overnight at 4uC with monoclonal antibody p15
INK4b (clone 15P06, 1:500, 0.4 mg IgG 1 /ml, Thermo Fischer Scientific, Fremont, CA, USA) and polyclonal rabbit antibody p57 KIP2 (1:1000, 0.14 mg IgG/ml, Sigma, St. Lous, MO, USA). The specimens were subsequently treated with goat anti-mouse IgG or goat anti-rabbit IgG for 30 min, EnVision TM Flex/HRP enzyme for 30 min, 393-diaminobenzidine tetrahydrochloride (DAB) for 10 min, counterstained with hematoxylin, dehydrated and mounted in Richard-Allan Scientific Cyto seal XYL (Thermo Scientific, Waltham, MA, USA). All of the sample series included appropriate positive controls, which included normal vulva (p15
INK4b
) and ovarian serous cystadenoma (p57 KIP2 ). Negative controls included substitution of the monoclonal antibody with mouse myceloma protein of the same subclass and concentration as the monoclonal antibody, or normal rabbit IgG of the same concentration as the polyclonal antibody.
Semiquantitative classes were used to describe the extent of staining (percent of positive tumor cells: absent, 0; ,10%, 1; 10-50%, 2; .50%, 3) and intensity (absent, 0; weak, 1; moderate, 2; strong, 3). By multiplying the extent and the intensity of the signal, product scores for nuclear staining were produced which ranging from 0 to 9. Protein levels for p15 INK4b and p57 KIP2 were classified as high when a score of 9 and low when a score of ,9. The cutoff value for the immunoreactivity was based on staining pattern observed in normal vulvar epithelium. Examination of immunostaining was performed in a blinded fashion by two observers (R.H. and J.M.N) with no knowledge of the clinicopathological variables, patient outcomes and cell cycle protein results from our previous studies [7, 8, 26] . All discordant scores were reviewed until a final agreement was obtained. ) and Linear-by-linear association were performed to fine associations between protein expression and clinicopathologic variables. Survival analysis was processed using the Kaplan and Meier estimation and log-rank test. Diseasespecific survival was calculated from the date of diagnosis to vulvar cancer related death. A Cox proportional hazards regression model was used for both univariate and multivariate evaluation of survival rates. In the multivariate analysis, a backward stepwise regression was performed with a p#0.05 as the inclusion criterion for variables in the univariate analysis. All calculations were processed using SPSS 18.0 statistical software package (SPSS, Chicago, IL, USA) and statistical significance was considered as p#0.05.
The vulvar carcinoma tissues in our cohort have been collected over an extensive period from 1977-2006. Due to the large 
Results
In 36 cases of normal vulvar squamous epithelium, nuclear staining for p15 INK4b and p57 KIP2 was identified in basal, parabasal, middle and top layers with a score of 9 ( Figure 1A and B). The immunostaining results in vulvar carcinomas are summarized in Table 1 . High p15
INK4b and p57 KIP2 immunostaining (score 9) in the nucleus was observed in 53/297 (18%) and 165/297 (56%) of the cases, respectively ( Figure 1C-D) , whereas low expression (score ,9) was identified in 244/297 (82%) and 132/297 (44%), respectively ( Figure 1E-F) .
The levels of p15 INK4b and p57 KIP2 in relation to clinicopathological parameters are shown in Table 2 . Low expression of p15
INK4b and p57 KIP2 were significantly correlated with large tumor diameter (p = 0.03 and p = 0.001, respectively) and deep invasion (p = 0.003 and p = 0.04, respectively). In addition, low expression of p57 KIP2 significantly correlated with younger age (p = 0.03) and a low level of cyclin D3 (p = 0.05).
By univariate analysis neither p15 INK4b nor p57 KIP2 were associated with disease-specific survival (p = 0.29 and p = 0.94). Because the prognosis of patients most likely do not dependent on the expression of one single member of the INK4 and CIP/KIP families but on an interplay between the different proteins, the previously determined p16
INK4a and p14 ARF status [7, 8] were combined with the expression of p15
INK4b and the previously identified p27 KIP1 and p21 CIP1 data [7] were combined with the expression of p57 KIP2 for each patient. Patients whose tumors expressed low levels of two or three of these INK4 proteins have a worse prognosis than those with only low levels of one or no protein (p = 0.02) (Figure 2) . Hovewer, the combination of the CIP/KIP members were not significantly correlated to clinical outcome (p = 0.78). By multivariat analysis, lymph node metastasis, vessel infiltration, tumor diameter and the combined p14 ARF / p15
INK4b /p16 INK4a status were of independent prognostic significance (Table 3) .
The results from the univariate analysis combining p14
INK4b /p16 INK4a status in a subgroup of patients who obtained surgical radicality (no rest tumor) is showed in Figure 3 . In this subgroup, multivariate analysis showed that the combined
INK4b /p16 INK4a status were of independent prognostic significance (Table 3) . However, p15
INK4b , p57 KIP2 and combined p21 CIP1 /p27 KIP2 /p57 KIP2 status were not significantly correlated to prognosis (data not shown). We also performed analyses of the subgroup of patients presenting with rest tumor. The parameters used are the same as those used in the analyses of patients who obtained surgical radically (no rest tumor). We were not able to reveal any prognostic significance (data not shown).
Discussion
Compared to the high level of p57 KIP2 in normal vulvar squamous epithelium, low p57 KIP2 expression was identified in 44% of vulvar carcinomas. Low p57 KIP2 expression has been reported in 89% of non small cell lung cancer [16] , 74% of bladder cancer [13] , 72% of breast cancer [27] , 71% of colorectal carcinoma [23] , 60% of ovarian carcinoma [17] , 50% of esophageal squamous cell carcinoma [15] and 45% of hepatocellular carcinoma [22, 28] . The wide range of the occurrence of low p57 KIP2 expression may be due to the various tumor types studied. In our current study, reduced p57 KIP2 level significantly correlated 
